In vitro activities of new macrolides and rifapentine against Brucella spp

J.Á. García-Rodríguez, Juan Luis Muñoz Bellido, Marı́a José Fresnadillo, I Trujillano

Antimicrobial Agents and Chemotherapy · 1993 · 41 citations · 14 references

DOIFull text

Open access

Concepts

Abstract

We have tested the in vitro activities of streptomycin, rifampin, tetracyclines, trimethoprim-sulfamethoxazole, erythromycin, four new macrolides (roxithromycin, azithromycin, clarithromycin, and dirithromycin), and rifapentine against 62 strains of Brucella spp. Azithromycin and clarithromycin were, respectively, eight- and twofold more active than erythromycins (MIC for 90% of strains = 2, 8, and 16 micrograms/ml, respectively). The activity of rifapentine was similar to that of rifampin (MIC for 90% of strains = 1 microgram/ml).

References

14